Author(s)

Aloy-Amadi Oluchi C.^1*, Ncharam Callista I.¹, Ezeh Chike C.², Akogu Okechukwu³, Emeka-Obi Obioma R.⁴, Nwabueze Jennifer U.¹

Affiliation(s)

¹Department of Medical Laboratory Science, Imo State University, Owerri, Nigeria.

²Department of Haematology, Federal University Teaching Hospital, Owerri, Nigeria.

³Department of Haematology, Federal University of Technology, Owerri, Nigeria. 

Corresponding Author

Aloy-Amadi Oluchi C.

ABSTRACT

Background: Sickle cell disease is a group of haemoglobin-related blood disorders typically inherited. It has remained a clinical burden in the world, particularly in Nigeria. Aim: This study was aimed at evaluating some haematological parameters liver enzymes and bilirubin in sickle cell diseased patients attending Federal University Teaching Hospital, Owerri, Imo State. Method: The study included a total of 60 individuals, 30 of them were sickle cell patients and 30 were apparently healthy individuals who served as controls. 7mls of venous blood was collected from each subject using the standard clean venipuncture technique. Samples for packed cell volume (PCV), haemoglobin (Hb) and total white blood cell (TWBC) estimations were aliquoted into EDTA containers while that of liver enzymes and bilirubin estimations were dispensed into plain tubes. Haematological parameters were determined using a hematological manual methods, while Aspartate transaminase (AST) and Alanine transaminase (ALT) concentrations were determined using Kinetic method and bilirubin was determined using Jendrassic and Grof method. The statistical analysis was done using software statistical package for social sciences (SPSS) version 22.0 and mean, standard deviation, student t-test and correlations were determined. Results: The mean values of PCV (22.17±4.35)% and Haemoglobin concentration (7.61±1.59)g/dl were significantly reduced in sickle cell patients when compared to controls (35.70±2.96)% and (11.92±1.26)g/dl,(p=0.000). The mean value of TWBC (17633.33±9859.99)cells/μl was significantly increased (p=0.000) in sickle cell patients when compared to controls (6765.00±1923.61)cells/μl,(p=0.000).The mean values of AST (17.77±12.97)IU/L, ALT (11.63±6.22)IU/L, Conjugated bilirubin (1.43±1.68)mg/dl and Total bilirubin (5.06±5.13)mg/dl were significantly increased in sickle cell patients when compared to controls (6.05±2.89)IU/L, (5.30±1.42)IU/L, (0.73±0.25)mg/dl and (1.40±0.32)mg/dl (p=0.000, p=0.000, p=0.003 and p=0.003). Conclusion: The findings have shown that sickle cell disease is associated with a decrease in PCV and haemoglobin, an increase in total white blood cell, AST, ALT and total bilirubin levels.

KEYWORDS

Sickle cell; Haemoglobin; Packed cell volume; White blood cell; Bilirubin; Liver enzymes

CITE THIS PAPER

Aloy-Amadi Oluchi C., Ncharam Callista I., Ezeh Chike C., Akogu Okechukwu, Emeka-Obi Obioma R., Nwabueze Jennifer U. Evaluation of some haematological parameters, liver enzymes and bilirubin in sickle cell diseased patients attending federal university teaching hospital, Owerri, Nigeria. World Journal of Biomedical Sciences. 2024, 2(3): 1-5. DOI: https://doi.org/10.61784/wjbs3008.

REFERENCES

[1] Akohoue SA, Shankar S, Milne GL, et al. Energy expenditure, inflammation, and oxidative stress in steady-state adolescents with sickle cell anemia. Pediatric Research, 2017, 61(2): 233–238.

[2] Allen C, Arora M, Barber RM, et al. Disease and injury incidence and prevalence collaborators. Gloal, Regional, and National Incidence, Prevalence, and years lived with disability for 310 Diseases and injuries, 1990- 2015, A systematic analysis for the global burden of disease study. The Lancet, 2015,  388(8): 1545-1602.

[3] Pecker LH, Lanzkron S. Sickle cell disease. Annals of Intern Medicine, 2021, 174(1): 1-9.

[4] Serjeant GR. One hundred years of sickle cell disease. British Journal of Haematology, 2020, 151 (5): 425–429.

[5] Kotila TA, Kayode A, Aduragbenro A, et al. Liver dysfunction in steady state sickle cell disease.Annals of Hepatology, 2015, 4: 261-263.

[6] Davis JS, Schulte W H, Zimmerman SA. Sustained long term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood, 2014, 103 (6): 2029-2030.

[7] Nsiah K, Dzogbefia V P, Ansong D, et al. Pattern of AST and ALT Changes in Relation to Heamolysis in sickle cell Disease. Clinical Medicine InsightsBlood Disorders, 2021, 4: 1- 9.

[8] Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. National Review of Disease Primers, 2018, 4:18-19.

[9] Ngasia B, Kazadi G, Loko G, et al. International symposium on sickle cell disease in central Africa. MedicalTropicals, 2017, 71: 535-566.

[10] Harkness DR. Hematological and clinical features of sickle cell diseases: A review. Hemoglobin, 2018, 4: 313-334.

[11] Johnson L, Bhutani VK, Boateng H. Guidelines for management of the jaundiced term and near term infant. Clinical Perinatology, 2015, 25: 555–574.

[12] Viktória R, Worrall VT, Butera V. Sickle-cell dactylitis. Journal of Bone Joint Surgery, 2016, 58 (8): 1161–1173.